Global animal health company Huvepharma® has received FDA approval for its generic monensin product, Monovet® 90 - the first generic monensin to be FDA approved in the United States.
The generic equivalent to Rumensin® 90, Monovet® 90 is an ionophore that alters rumen fermentation patterns to increase feed efficiency, particularly in feedlot cattle, and to improve body weight gain in cattle at pasture.
In addition, Monovet® 90 is also FDA-approved for use in combination with a number of other drug feed additive products in the manufacture of Type B and C medicated feeds. The most recent round of FDA approvals expands the use of Monovet® 90 for use in combination with other feed additives commonly used in rations for feedlot cattle including decoquinate for coccidiosis prevention and tilmicosin for respiratory disease therapy.
"By bringing the first generic monensin product to the marketplace, Huvepharma® offers livestock producers a new cost-effective choice, while providing the same benefits of dosage, chemical identity, potency, quality, safety and route of administration," says Glen Wilkinson, president of Huvepharma US.
For the full list of all current medicated feed combinations or to discuss how Monovet® 90 can add performance to your business, contact customerserviceusa@huvepharma.com.
